Transmedics Group Inc (TMDX) valuation
Transmedics Group P/E ratio history
Transmedics Group trades at 17.1 times its earnings over the last twelve months and 35.1 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $121.65 | $4.87 | 25.0 | 45.3 |
| Dec 31, 2024 | $62.35 | $1.01 | 61.7 | 48.0 |
| Dec 31, 2023 | $78.93 | -$0.77 | n/m | — |
| Dec 31, 2022 | $61.72 | -$1.23 | n/m | — |
| Dec 31, 2021 | $19.16 | -$1.60 | n/m | — |
| Dec 31, 2020 | $19.90 | -$1.16 | n/m | — |
| Dec 28, 2019 | $18.59 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Transmedics Group valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Transmedics GroupTMDX | $2.28B | 17.1 | 35.1 | 3.4 |
| ProgynyPGNY | $2.29B | 31.7 | 13.3 | 1.7 |
| Arcus BiosciencesRCUS | $2.29B | — | — | 19.6 |
| Harmony Biosciences HldgHRMY | $2.24B | 12.6 | 6.3 | 2.3 |
| BiohavenBHVN | $2.32B | — | — | — |
| Prestige Consumer HealthcarePBH | $2.32B | 13.7 | 10.4 | 2.1 |
| NeogenomicsNEO | $2.23B | — | 58.8 | 2.8 |
| Vera TherapeuticsVERA | $2.22B | — | — | — |
| Addus HomecareADUS | $2.34B | 22.0 | 17.2 | 1.6 |
| Peer median | 17.9 | 13.3 | 2.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: TMDX financials · TMDX returns
No forecast, no recommendation. This page describes Transmedics Group Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.